查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466634

注射市场：按分子类型、药物类别、注射途径和应用划分 - 2024-2030 年全球预测

Injectable Drugs Market by Molecule Type (Large Molecule, Small Molecule), Drug Class (Blood Factors, Cytokines, Immunoglobulin), Injection Routes, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年註射剂市场规模为5,633亿美元，预计2024年将达6,170.4亿美元，2030年将达1,0885.5亿美元，复合年增长率为9.86%。

注射剂市场包括透过静脉（IV）、肌肉内（IM）和皮下（SC）注射途径进行的药物和治疗方法的销售和分销。经营抗生素、胰岛素、疫苗、肿瘤治疗药等治疗各种疾病所必需的药品。注射剂有多种用途，从紧急医疗护理到治疗慢性疾病的日常用药。除了在医院和诊所使用之外，自动注射器的进步也导致其在自我护理环境中使用。有几个因素正在推动注射药物市场的开拓，包括慢性疾病负担的增加、预填充药物和自註射药物的使用增加以及稳定的药物输送载体用于癌症治疗的持续实践。然而，该市场面临研发成本高、监管合规成本以及恶劣条件下复杂的製造流程等限制和挑战。同时，由于注射剂的快速开发和核准以及注射剂製造商之间的策略联盟，新的机会正在出现。此外，提高药物传递的安全性、便利性和有效性可以提高患者的依从性并改善结果。

主要市场统计
基准年[2023] 5633亿美元
预测年份 [2024] 6170.4亿美元
预测年份 [2030] 1,088,550 百万美元
复合年增长率（%） 9.86%

药物类别：用于细胞讯号传导的细胞激素注射越来越受欢迎

凝血必需的血液因子是用于治疗血友病和其他凝血障碍以及预防出血的注射。血液因子可以从人类血浆中或透过重组基因技术获得。 A型血友病是需要这些治疗的最常见疾病。细胞激素是一类广泛的可注射蛋白质，对于免疫系统中的细胞讯号传导非常重要。它们包括干扰素、白细胞介素和集落刺激因子，用于治疗癌症和自体免疫疾病。免疫球蛋白是免疫系统的重要组成部分，常用于各种免疫力缺乏症候群和自体免疫疾病。这些药物提供免疫系统对抗病原体所需的抗体。胰岛素是肽激素，对于调节血糖值至关重要。胰岛素主要用于糖尿病患者，当身体无法自然产生足够的胰岛素时使用。单株抗体 (mAb) 是模仿免疫系统抵抗有害病原体能力的工程分子。这些药物正在改变多种疾病的治疗方法，包括癌症、自体免疫疾病和感染疾病。肽激素包括胰岛素以外的多种注射激素，例如生长激素、抗糖尿病Glucagon-Like Peptide-1(GLP-1)促效剂和抑钙素。这些激素发挥多种作用，包括调节生长、葡萄糖代谢和骨稳态。

应用：扩大注射剂在自体免疫疾病治疗的应用

自体免疫疾病注射可治疗多种疾病，包括类风湿性关节炎、多发性硬化症和克隆氏症。生物製药是注射药物的子类，通常采用有针对性的方法来调节免疫系统。注射剂是首选，因为它们起效快且比口服药物疗效更高。心血管疾病注射剂旨在治疗心臟衰竭、心律不整和高血压等疾病。这些注射通常在紧急情况下发挥关键作用，在抗凝血剂和凝血因子等治疗延迟可能致命时提供快速治疗。在感染疾病中，注射药物对于抗病毒、抗生素和抗真菌药物至关重要，特别是当需要快速达到高血中浓度或无法口服给药时。它们对于抗病毒药物、抗生素和抗真菌药物至关重要，特别是当需要快速达到高血中浓度或无法口服给药时。神经注射剂可治疗阿兹海默症、多发性硬化症和偏头痛等疾病。单株抗体在这一领域很重要，因为它们能够穿过血脑障壁。癌症领域的注射药物包括化疗药物、荷尔蒙疗法药物、免疫治疗药物等，对于各种癌症的治疗至关重要。注射剂是优选的，因为需要达到高局部浓度并避免胃肠道吸收问题。注射性疼痛管理药物，如鸦片类药物和非类固醇消炎剂(NSAID)，因其在急性、慢性和术后疼痛管理中的速度和有效性而受到青睐。注射应用领域的比较表明，每个领域都满足医疗保健领域的独特需求。自体免疫疾病需要长期治疗方法，注射剂可以提供持久的缓解。相较之下，注射心血管药物往往较为紧急，需要快速的生理反应。用于感染疾病的注射药物必须具有广泛且快速的作用，以有效控制感染疾病。在神经病学领域，考虑到血脑障壁的问题，注射剂具有能够标靶给药的优点。注射型癌症药物透过在肿瘤部位高浓度输送来提供标靶治疗的好处。最后，注射疼痛管理可以立即缓解口服药物通常无法达到的急性、严重疼痛。

区域洞察

在美洲，特别是在美国和加拿大，由于糖尿病和癌症等疾病的流行，注射药物的需求量很大。先进的医疗基础设施和高昂的人均医疗成本正在推动新註射技术的创新和采用。在这些市场中，药物功效、安全性和易用性影响顾客的购买行为。由于巴西、阿根廷和智利等国医疗保健设施的改善、经济稳定性的增强以及政府对医疗改革的支持，南美注射市场正在稳步增长。欧洲拥有发达的医疗体系和优惠的报销政策，注射剂市场正作为新兴市场发展。由于先进治疗方法的普及，东欧国家的成长率正在加速。包括沙乌地阿拉伯和阿联酋在内的中东地区因其发达的医疗基础设施和不断增加的私营部门投资而成为一个充满前景的市场。与此同时，非洲在引入註射疗法方面正在取得进展，但面临着负担能力和药物取得的挑战。由于经济成长、医疗保健行业的扩张以及生物製药研究投资的增加，亚太地区已成为成长最快的注射剂市场。中国、印度和日本等国家处于领先地位，对学名药和创新註射剂的需求都很高。在中国，国内製造和引进外资活跃，服务广大的国内市场。日本以其技术进步而闻名，并大力投资药物研发，包括下一代注射剂。印度的製药业发展迅速，是一个庞大的注射剂市场。低成本製造和不断壮大的中阶有利于影响更实惠的注射药物选择的购买行为。

FPNV定位矩阵

FPNV 定位矩阵对于评估注射剂市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对注射剂市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争力评估及资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.注射剂市场规模及预测如何？

2.注射剂市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3.注射剂市场的技术趋势和法规结构是什么？

4.注射剂市场主要供应商的市场占有率是多少？

5.进入註射剂市场的合适模式和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病负担增加
      • 预填充和自行注射药物的使用增加
      • 受控药物传输载体在癌症治疗中的持续实践
    • 抑制因素
      • 产品回收数量增加
    • 机会
      • 注射剂的快速开发和核准
      • 注射剂製造商之间的策略联盟
    • 任务
      • 製造流程复杂，注射剂短缺
  • 市场区隔分析
    • 药物类别：用于细胞讯号传导的细胞细胞激素注射蛋白越来越受欢迎
    • 应用：扩大注射剂在自体免疫疾病治疗的应用
  • 市场趋势分析
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析
  • 客户客製化

第六章註射剂市场：依分子类型

  • 高分子
  • 小分子

第七章註射剂市场：依药物类别

  • 血液因素
  • 细胞激素
  • 免疫球蛋白
  • 胰岛素
  • 单株抗体
  • 肽激素

第八章註射剂市场：依注射途径

  • 肌肉注射
  • 眼
  • 椎管内的
  • 静脉
  • 皮下的

第九章註射剂市场：依应用分类

  • 自体免疫疾病
  • 心血管疾病
  • 感染疾病
  • 神经病学
  • 肿瘤学
  • 疼痛

第10章美洲注射剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太注射剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲注射市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争情境分析
    • Sun Pharma 与 Taro 宣布合併协议
    • Glenmark 在印度推出流行抗糖尿病药物Liraglutide的生物相似药
    • 百时美施贵宝的Opdivo注射液达到肾癌临床试验的关键目标

第14章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-742BD517FCA4

[199 Pages Report] The Injectable Drugs Market size was estimated at USD 563.30 billion in 2023 and expected to reach USD 617.04 billion in 2024, at a CAGR 9.86% to reach USD 1,088.55 billion by 2030.

The injectable drugs market comprises sales and distribution of medications and therapies that are administered through intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection routes. The market caters to various drugs, including antibiotics, insulin, vaccines, and oncology treatments, that are integral in treating multiple diseases and medical conditions. Injectable drugs have diverse applications ranging from emergency care to routine administration of chronic disease medications. They are used in hospitals, clinics, and, increasingly, self-care settings due to advancements in auto-injection devices. Several factors, such as the rising burden of chronic diseases, the growing use of prefilled and self-injectable drugs, and the ongoing practice of steady drug delivery vehicles for cancer treatment, drive the development of the injectable drugs market. However, the market faces limitations and challenges, including high research and development costs, regulatory compliance costs, and complex manufacturing processes under stringent conditions. On the other hand, new opportunities are emerging due to rapid developments and approvals in injectable drugs and strategic alliances among manufacturers for injectable drugs. Moreover, improving drug delivery methods' safety, convenience, and efficacy can lead to increased patient compliance and better outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 563.30 billion
Estimated Year [2024] USD 617.04 billion
Forecast Year [2030] USD 1,088.55 billion
CAGR (%) 9.86%

Drug Class: Increasing preference for cytokines injectable protein for cell signaling

Blood factors, essential for blood clotting, are injectable agents used to treat and prevent bleeding in individuals with hemophilia and other clotting disorders. They are derived either from human plasma or through recombinant technology. Hemophilia A and B are the most common disorders requiring these treatments. Cytokines are a broad category of injectable proteins critical in cell signaling within the immune system. They include interferons, interleukins, and colony-stimulating factors and are used in treating cancers and autoimmune conditions. Immunoglobulins are essential immune system components commonly used for various immunodeficiency syndromes and autoimmune diseases. These drugs provide necessary antibodies for the immune system to combat pathogens. Insulin is a peptide hormone vital for the regulation of blood glucose levels. It is primarily administered to individuals with diabetes when their body cannot produce sufficient insulin naturally. Monoclonal Antibodies (mAbs) are engineered molecules that imitate the immune system's capacity to fight off harmful pathogens. These drugs have transformed treatment across a spectrum of conditions, including cancer, autoimmune diseases, and infectious diseases. Peptide hormones encompass a variety of injectable hormones other than insulin, such as growth hormone, glucagon-like peptide-1 (GLP-1) agonists for diabetes, and calcitonin. They play various roles, including regulating growth, glucose metabolism, and bone homeostasis.

Application: Growing application of injectable drugs for treating autoimmune diseases

Injectable drugs for autoimmune diseases treat various conditions, including rheumatoid arthritis, multiple sclerosis, and Crohn's disease. Biologics, a subclass of injectable drugs, are often prescribed due to their targeted approach to modulating the immune system. The need-based preference for injectables stems from their quick onset of action and higher efficacy than oral medications. Injectable drugs for cardiovascular diseases aim to manage conditions such as heart failure, arrhythmia, and hypertension. These injections are often critical in emergency settings, providing rapid action where delayed treatment, such as anticoagulants or clotting factors, can be fatal. For infectious diseases, injectable drugs are crucial for antivirals, antibiotics, and antifungals, especially when high blood concentrations are required quickly, or oral administration is not feasible. They are critical in hospital settings for severe or resistant infections. Neurology injectables treat disorders, including Alzheimer's, multiple sclerosis, and migraines. Monoclonal antibodies are significant in this segment for their ability to cross the blood-brain barrier. Oncology injectables include chemotherapy agents, hormonal therapies, and immunotherapies, essential for treating various cancers. The preference for injections comes from the need to achieve high local concentration and to bypass gastrointestinal absorption issues. Injectable drugs for pain management, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), are preferred in acute, chronic, and post-operative pain management for their speed and efficacy. In comparing the application segments for injectable drugs, it is apparent that each serves a distinct need in the healthcare sphere. Autoimmune diseases require long-term treatment regimens where injectables offer sustained relief. In contrast, cardiovascular injectable drugs are often emergency-related and demand rapid physiological responses. Infectious disease injectables must be broad-spectrum and rapidly acting to curb infections effectively. Neurology benefits from the targeted delivery achieved by injectables, a distinct advantage given the blood-brain barrier challenge. Injectable oncology drugs offer the benefit of targeted therapy with higher concentrations at the tumor site. Lastly, pain management with injectables provides immediate relief from acute and severe pain, which is often unattainable with oral medications.

Regional Insights

In the Americas, particularly in the United States and Canada, there is a high demand for injectable drugs due to the prevalence of diseases such as diabetes and cancer. Advanced healthcare infrastructure and high per capita healthcare expenditure drive the innovation and adoption of new injection technologies. Drug efficacy, safety profiles, and ease of use influence customer purchasing behavior in these markets. South America's market for injectable drugs is growing steadily due to improving healthcare facilities, increasing economic stability, and governmental support for healthcare reforms in countries such as Brazil, Argentina, and Chile. Europe represents a developing injectable drug market with well-established healthcare systems and favorable reimbursement policies. Eastern European countries are experiencing faster growth rates due to increased accessibility to advanced therapeutics. The Middle East, with countries such as Saudi Arabia and the UAE, shows a promising injectable drugs market due to rising healthcare infrastructure and increasing private sector investments. Africa, on the other hand, is progressively adopting injectable drug therapies but faces challenges related to affordability and access to medicine. The APAC region is emerging as the fastest-growing market for injectable drugs, driven by economic growth, expanding healthcare sectors, and increasing investments in biopharmaceutical research. Countries such as China, India, and Japan are at the forefront, with a high demand for both generic and innovative injectable drugs. In China, local manufacturing and foreign investment are extensive, catering to a vast domestic market. Japan is known for its technological advancements and invests heavily in pharmaceutical R&D, including next-generation injectable treatments. With a burgeoning pharmaceutical industry, India offers a large market for injectable drugs. Low-cost manufacturing and a growing middle class impact purchasing behaviors favorably toward more affordable injectable options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Injectable Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Injectable Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Injectable Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Baxter International Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Chiesi Farmaceutici S.p.A., Cipla Limited, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories Ltd., Eagle Pharmaceuticals, Inc., Eli Lilly and Company, EVER Neuro Pharma GmbH, F. Hoffmann-La Roche Ltd., Ferring B.V., Fresenius Kabi AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., SCHOTT PHARMA AG & CO. KGAA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Injectable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Molecule Type
    • Large Molecule
    • Small Molecule
  • Drug Class
    • Blood Factors
    • Cytokines
    • Immunoglobulin
    • Insulin
    • Monoclonal Antibodies
    • Peptide Hormone
  • Injection Routes
    • Intramuscular
    • Intraocular
    • Intrathecal
    • Intravenous
    • Subcutaneous
  • Application
    • Autoimmune Diseases
    • Cardiovascular Diseases
    • Infectious Diseases
    • Neurology
    • Oncology
    • Pain
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Injectable Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Injectable Drugs Market?

3. What are the technology trends and regulatory frameworks in the Injectable Drugs Market?

4. What is the market share of the leading vendors in the Injectable Drugs Market?

5. Which modes and strategic moves are suitable for entering the Injectable Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Burden of Chronic Diseases
      • 5.1.1.2. Growing Use of Prefilled and Self-Injectable Drugs
      • 5.1.1.3. Ongoing Practice of Controlled Drug Delivery Vehicles for Cancer Treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Rise in Incidences of Product Recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Rapid Developments and Approvals in Injectable Drugs
      • 5.1.3.2. Strategic Alliances Among Manufacturers for Injectable Drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex Manufacturing Process and Shortages of Injectable Drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Increasing preference for cytokines injectable protein for cell signaling
    • 5.2.2. Application: Growing application of injectable drugs for treating autoimmune diseases
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Injectable Drugs Market, by Molecule Type

  • 6.1. Introduction
  • 6.2. Large Molecule
  • 6.3. Small Molecule

7. Injectable Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Blood Factors
  • 7.3. Cytokines
  • 7.4. Immunoglobulin
  • 7.5. Insulin
  • 7.6. Monoclonal Antibodies
  • 7.7. Peptide Hormone

8. Injectable Drugs Market, by Injection Routes

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intraocular
  • 8.4. Intrathecal
  • 8.5. Intravenous
  • 8.6. Subcutaneous

9. Injectable Drugs Market, by Application

  • 9.1. Introduction
  • 9.2. Autoimmune Diseases
  • 9.3. Cardiovascular Diseases
  • 9.4. Infectious Diseases
  • 9.5. Neurology
  • 9.6. Oncology
  • 9.7. Pain

10. Americas Injectable Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Injectable Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Injectable Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sun Pharma and Taro announce merger agreement
    • 13.3.2. Glenmark launched Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India
    • 13.3.3. Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. INJECTABLE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INJECTABLE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. INJECTABLE DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INJECTABLE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAOCULAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PAIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PAIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 118. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 120. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. CHINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. CHINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. CHINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 126. CHINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 127. CHINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 128. CHINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 129. CHINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. CHINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. INDIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. INDIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. INDIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 134. INDIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 135. INDIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 136. INDIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 137. INDIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. INDIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 142. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 143. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 144. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 145. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. JAPAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. JAPAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. JAPAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 150. JAPAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 151. JAPAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 152. JAPAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 153. JAPAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. JAPAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 158. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 159. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 160. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 161. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 166. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 168. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 174. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 175. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 176. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 177. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 182. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 184. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 190. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 191. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 192. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 193. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. THAILAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. THAILAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. THAILAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 198. THAILAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 199. THAILAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 200. THAILAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 201. THAILAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. THAILAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 206. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 207. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 208. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 209. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 221. DENMARK INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. DENMARK INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. DENMARK INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 224. DENMARK INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 225. DENMARK INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 226. DENMARK INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 227. DENMARK INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 228. DENMARK INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 229. EGYPT INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. EGYPT INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. EGYPT INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 232. EGYPT INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 233. EGYPT INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 234. EGYPT INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 235. EGYPT INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 236. EGYPT INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 237. FINLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. FINLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. FINLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 240. FINLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 241. FINLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 242. FINLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 243. FINLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. FINLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. FRANCE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. FRANCE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. FRANCE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 248. FRANCE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 249. FRANCE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 250. FRANCE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 251. FRANCE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 252. FRANCE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 253. GERMANY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. GERMANY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. GERMANY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 256. GERMANY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 257. GERMANY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 258. GERMANY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 259. GERMANY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 260. GERMANY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 261. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 264. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 265. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 266. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 267. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. ITALY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. ITALY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. ITALY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 272. ITALY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 273. ITALY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 274. ITALY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 275. ITALY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 276. ITALY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 280. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 281. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 282. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 283. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 284. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 285. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 288. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 289. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 290. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 291. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 292. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 293. NORWAY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 294. NORWAY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 295. NORWAY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 296. NORWAY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 297. NORWAY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 298. NORWAY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 299. NORWAY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 300. NORWAY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 301. POLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. POLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. POLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 304. POLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 305. POLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 306. POLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 307. POLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 308. POLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 309. QATAR INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. QATAR INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. QATAR INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 312. QATAR INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 313. QATAR INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 314. QATAR INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 315. QATAR INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 316. QATAR INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 317. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 320. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 321. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 322. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 323. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 324. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 325. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 328. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 329. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 330. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 331. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 332. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 333. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 336. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 337. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 338. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 339. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 340. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 341. SPAIN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 342. SPAIN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 343. SPAIN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 344. SPAIN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 345. SPAIN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 346. SPAIN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 347. SPAIN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 348. SPAIN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 349. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 352. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 353. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2023 (USD MILLION)
  • TABLE 354. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2024-2030 (USD MILLION)
  • TABLE 355. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 356. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 357. SWITZERLAND INJECTABLE D